Bay Area's Global Blood Therapeutics Terminates Lung Disease Program Post author:Sam Post published:October 22, 2017 Post category:BioPharma The company is shuttering its GBT440 program to treat idiopathic pulmonary fibrosis (IPF). Source: BioSpace You Might Also Like Protagonist Craters After Discontinuing Phase IIb Ulcerative Colitis Study March 25, 2018 <b>Elligo Health Research</b> Names <b>Deirdre BeVard</b> As Chief Operating Officer August 29, 2017 2 Bay Area Biotechs That Jumped While Its Peers Cratered February 6, 2018